Splenic marginal zone lymphoma – European Clinical Trials Information Network

Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

Wed, 29 Apr 2026 14:59:48 +0000

The study focuses on patients with Marginal Zone Lymphoma (MZL), a type of blood cancer that affects specific areas of the lymphatic system. The research will test a medication called obinutuzumab (Gazyvaro), which is given through an intravenous infusion directly into the bloodstream.

The purpose of this research is to evaluate how well obinutuzumab works and what side effects it may cause when used as a first treatment for people with MZL who cannot receive local treatments or for whom local treatments have not worked. The medication will be given as a single treatment, meaning it will not be combined with other cancer medications.

During the study, participants will receive obinutuzumab through an intravenous infusion at a dose of 1,000 mg. The treatment period may last up to 30 months. Throughout the study, doctors will monitor the participants’ response to treatment and track any side effects that may occur. The study will also look at how the treatment affects participants’ quality of life and whether any other health conditions develop over time.

Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

Wed, 29 Apr 2026 14:59:36 +0000

This clinical trial is focused on studying the treatment of Marginal Zone Lymphoma (MZL), a type of cancer that affects the lymphatic system. The study will use two medications: Copanlisib and Rituximab. Copanlisib is a medication that helps to block certain proteins that cancer cells need to grow, while Rituximab is a type of protein that targets and helps destroy cancer cells. The purpose of the study is to test how effective and safe these medications are when used together in patients who need treatment for MZL, especially those who have not responded to or are not eligible for local treatments like surgery or radiotherapy.

Participants in the study will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will last for about 12 months, during which the response to the treatment will be closely monitored. This includes checking for complete remission, which means the disappearance of all signs of cancer in response to treatment. The study will also document any side effects and how the treatment affects the quality of life of the participants. The goal is to understand how well the combination of Copanlisib and Rituximab works in treating MZL and to identify any potential risks associated with the treatment.

Throughout the study, participants will have regular visits for drug administration, imaging studies like MRI or CT scans, and laboratory tests to monitor their health and the progress of the treatment. The study will also track the time it takes for the best response to occur, how long the response lasts, and the overall survival of the participants. This information will help researchers determine the effectiveness of the treatment and its impact on the participants’ lives.

Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

Wed, 29 Apr 2026 14:30:00 +0000

This clinical trial is focused on studying a type of cancer called Splenic Marginal Zone Lymphoma (SMZL), which affects a part of the immune system known as the spleen. The study is investigating the effectiveness of a treatment that combines two medications: Rituximab and Zanubrutinib. Rituximab is a medication that is given through an infusion into a vein, while Zanubrutinib, also known by its code name BGB-3111, is taken orally in capsule form. The purpose of the study is to see if adding Zanubrutinib to Rituximab is more effective than using Rituximab alone in treating patients who have not received any previous treatment for their SMZL.

Participants in the study will be randomly assigned to receive either the combination of Rituximab and Zanubrutinib or Rituximab alone. The study will last for up to 24 months, during which time the participants will receive their assigned treatment. The researchers will monitor the participants’ health and the progression of their lymphoma throughout the study period. The main goal is to determine how long the participants can live without their disease getting worse, which is known as progression-free survival.

By comparing the two treatment approaches, the study aims to provide valuable information on whether the addition of Zanubrutinib can improve outcomes for patients with SMZL. The results could potentially lead to better treatment options for individuals diagnosed with this type of lymphoma. Participants will be closely monitored for any side effects or adverse reactions to the medications, ensuring their safety throughout the trial.